Trial · NCT00065611

Steroid Treatment for Kidney Disease

NCT00065611, Phase 3, Completed, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); results first posted 2011-10-28

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Steroid Treatment for Kidney Disease. Trials, record NCT00065611. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00065611

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Steroid Treatment for Kidney Disease
NCT number: NCT00065611
Status: Completed
Phases: Phase 3
Enrollment: 8 participants, actual
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions: Nephrosis, Focal Lipoid Glomerulosclerosis
Interventions: Oral dexamethasone
First posted: 2003-07-29
Last updated: 2011-10-28
Results first posted: 2011-10-28

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks	48 weeks from baseline	Complete remission is defined as proteinuria \<0.3 g/d. Partial remission is defined as a 50% fall in proteinuria compared to baseline, proteinuria \<3.5 g/d, and a preserved estimated glomerular filtration rate (eGFR), specified as \>60% of baseline. Limited response is defined as a 50% fall in proteinuria compared to baseline. All other outcomes are described as non-response.
Secondary	Urine Protein	48 weeks from baseline
Secondary	CKD-EPI eGFR	48 weeks from baseline	Estimate glomerular filtration rate (eGFR) using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks	48 weeks from baseline	ITT	participants	NUMBER
SECONDARY	Urine Protein	48 weeks from baseline		g/d	MEAN
SECONDARY	CKD-EPI eGFR	48 weeks from baseline		ml/min/1.73m^2	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks	2 Doses Every 2 Weeks Arm	Limited response	1		participants
Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks	4 Doses Every 4 Weeks Arm	Limited response	1		participants
Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks	2 Doses Every 2 Weeks Arm	Non-response	2		participants
Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks	4 Doses Every 4 Weeks Arm	Non-response	1		participants
Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks	2 Doses Every 2 Weeks Arm	Partial remission	1		participants
Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks	4 Doses Every 4 Weeks Arm	Partial remission	1		participants
Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks	2 Doses Every 2 Weeks Arm	Complete remission	0		participants
Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks	4 Doses Every 4 Weeks Arm	Complete remission	0		participants
Urine Protein	2 Doses Every 2 Weeks Arm		3.6	Standard Deviation 0.7	g/d
Urine Protein	4 Doses Every 4 Weeks Arm		6.2	Standard Deviation 4.8	g/d

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	2 Doses Every 2 Weeks Arm	4
Overall Study	STARTED	4 Doses Every 4 Weeks Arm	4
Overall Study	COMPLETED	2 Doses Every 2 Weeks Arm	4
Overall Study	COMPLETED	4 Doses Every 4 Weeks Arm	3
Overall Study	NOT COMPLETED	2 Doses Every 2 Weeks Arm	0
Overall Study	NOT COMPLETED	4 Doses Every 4 Weeks Arm	1

Source ClinicalTrials.gov

Adverse events22

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Headache	General disorders	2 Doses Every 2 Weeks Arm	1	4	1
other	Headache	General disorders	4 Doses Every 4 Weeks Arm	0	4	0
other	sleep disturbance	General disorders	2 Doses Every 2 Weeks Arm	1	4	1
other	sleep disturbance	General disorders	4 Doses Every 4 Weeks Arm	1	4	1
other	Mood swings	General disorders	2 Doses Every 2 Weeks Arm	2	4	2
other	Mood swings	General disorders	4 Doses Every 4 Weeks Arm	1	4	1
other	Change in appetite	General disorders	2 Doses Every 2 Weeks Arm	0	4	0
other	Change in appetite	General disorders	4 Doses Every 4 Weeks Arm	1	4	1
other	Weight gain	General disorders	2 Doses Every 2 Weeks Arm	0	4	0
other	Weight gain	General disorders	4 Doses Every 4 Weeks Arm	1	4	1

1 to 10 of 22Source ClinicalTrials.gov

See all 22 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	2 Doses Every 2 Weeks Arm
Total, all-cause mortality	4 Doses Every 4 Weeks Arm
Total, other adverse events	2 Doses Every 2 Weeks Arm	3	4
Total, other adverse events	4 Doses Every 4 Weeks Arm	1	4
Total, serious adverse events	2 Doses Every 2 Weeks Arm	1	4
Total, serious adverse events	4 Doses Every 4 Weeks Arm	2	4

Source ClinicalTrials.gov

Papers4

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
3746552	BACKGROUND	PubMed
9260238	BACKGROUND	PubMed
11322372	BACKGROUND	PubMed
35224732	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
2 Doses Every 2 Weeks Arm vs 4 Doses Every 4 Weeks Arm: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00065611

GET https://conductscience.org/api/trials/v1/NCT00065611/events?page=2

API reference For AI assistants